We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Glucose–Thymidine Ratio as a Metabolism Index Using 18 F-FDG and 18 F-FLT PET Uptake as a Potential Imaging Biomarker for Evaluating Immune Checkpoint Inhibitor Therapy.
- Authors
Oh, Sera; Youn, Hyewon; Paeng, Jin Chul; Kim, Young-Hwa; Lee, Chul-Hee; Choi, Hongyoon; Kang, Keon Wook; Chung, June-Key; Cheon, Gi Jeong
- Abstract
Immune checkpoint inhibitors (ICIs) are widely used in cancer immunotherapy, requiring effective methods for response monitoring. This study evaluated changes in 18F-2-fluoro-2-deoxy-D-glucose (FDG) and 18F-fluorothymidine (FLT) uptake by tumors following ICI treatment as potential imaging biomarkers in mice. Tumor uptakes of 18F-FDG and 18F-FLT were measured and compared between the ICI treatment and control groups. A combined imaging index of glucose–thymidine uptake ratio (GTR) was defined and compared between groups. In the ICI treatment group, tumor growth was effectively inhibited, and higher proportions of immune cells were observed. In the early phase, 18F-FDG uptake was higher in the treatment group, whereas 18F-FLT uptake was not different. There was no difference in 18F-FDG uptake between the two groups in the late phase. However, 18F-FLT uptake of the control group was markedly increased compared with the ICI treatment group. GTR was consistently higher in the ICI treatment group in the early and late phases. After ICI treatment, changes in tumor cell proliferation were observed with 18F-FLT, whereas 18F-FDG showed altered metabolism in both tumor and immune cells. A combination of 18F-FLT and 18F-FDG PET, such as GTR, is expected to serve as a potentially effective imaging biomarker for monitoring ICI treatment.
- Subjects
IMMUNE checkpoint inhibitors; BIOMARKERS; TUMOR growth; METABOLISM
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 16, p9273
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms23169273